in vitro News and Research

RSS

CSP analogues may attenuate S. pneumoniae virulence, resistance

The spread of virulent, antibiotic-resistant strains of Streptococcus pneumoniae may be controllable through the use of competence-stimulating peptide analogues, US researchers believe.

24 Mar 2014

Systemic stem cell therapy reduces malignant mesothelioma growth

Systemic delivery of stem cells expressing an apoptosis-inducing protein can successfully incorporate into malignant pleural mesothelioma cells and subsequently induce their death, according to preclinical study findings.

19 Mar 2014

Findings open way to identification of new cancer drugs to fight acute myeloid leukemia

The Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal (UdeM), in collaboration with the Maisonneuve-Rosemont Hospital's Quebec Leukemia Cell Bank, recently achieved a significant breakthrough thanks to the laboratory growth of leukemic stem cells, which will speed up the development of new cancer drugs.

18 Mar 2014

Sparton completes all-cash transaction to acquire Aubrey Group

Sparton Corporation announces that it completed an all-cash transaction to acquire Aubrey Group, Inc., an $8 million revenue business, on March 17, 2014. Aubrey will continue to service its current and future customers out of its Irvine, CA location.

18 Mar 2014

Researchers examine how diabetes drug can benefit cancer patients

For several years, a class of anti-diabetic drugs known as biguanides, has been associated with anti-cancer properties. A number of retrospective studies have shown that the widely used diabetes drug metformin can benefit some cancer patients.

18 Mar 2014

Bisphenol A may promote prostate tumourigenesis

Bisphenol A, an organic compound that is ubiquitous in plastic products, may have a direct tumourigenic effect in the prostate, US researchers have shown.

17 Mar 2014

Dartmouth researchers develop unique approach to treat Chronic Lymphocytic Leukemia

Dartmouth researchers have developed a novel and unique approach to treating Chronic Lymphocytic Leukemia (CLL), a form of blood cancer that often requires repeated chemotherapy treatments to which it grows resistant.

17 Mar 2014

Study shows effect of oral fungal yeast in inhibiting thrush

Scientists at Case Western Reserve School of Medicine and University Hospitals (UH) Case Medical Center have discovered how the beneficial fungal yeast, Pichia, holds at bay a harmful fungal yeast, Candida.

14 Mar 2014

Venaxis' APPY1 Test for appendicitis shows positive results in pivotal U.S. study

Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced positive top-line results from its pivotal U.S. study.

14 Mar 2014

AnaptysBio announces strategic immuno-oncology collaboration with TESARO

AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced a strategic immuno-oncology collaboration with TESARO, Inc., an oncology-focused biopharmaceutical company.

13 Mar 2014

CRO services division of Galapagos to be acquired by Charles River Laboratories

Charles River Laboratories International, Inc. announced today that it has entered into a definitive agreement to acquire the CRO services division of Galapagos NV (Euronext: GLPG), which includes both Argenta and BioFocus.

13 Mar 2014

Study provides insight into the mechanisms underlying diabetic peripheral neuropathy

Iron overload can lead to cytotoxicity, and it is a risk factor for diabetic peripheral neuropathy. However, the underlying mechanism remains unclear.

13 Mar 2014

UNIGE discovers new class of molecules toxic for Plasmodium pathogen

The malaria parasite is particularly pernicious since it is built to develop resistance to treatments. The lack of new therapeutic approaches also contributes to the persistence of this global scourge.

12 Mar 2014

Promethera Biosciences, EMD Millipore partner to develop ready-to-use microfluidic perfusion liver assay

Promethera Biosciences, a company that develops innovative therapies for the treatment of liver diseases, today announces a collaboration with EMD Millipore to develop an improved ready-to-use microfluidic perfusion liver assay. This new product is designed to perform more robust studies in pre-clinical toxicity and drug metabolism.

11 Mar 2014

Homologous recombination technology for research applications in genetically modified rodents: an interview with Alexandre Fraichard, CEO, genOway

Homologous recombination is a technology that enables the targeted insertion of nucleotide fragments into the genome of a cell. It is called ‘homologous’ because it uses a sequence that is a homologue to the sequence being targeted in a gene, so that the sequence is recognized.

10 Mar 2014

Tubulin protein is a well-validated cancer drug target

Tubulin, the building-block protein of cellular microtubules, is a well-validated cancer drug target: Disrupting tubulin polymerization affects cytoskeletal function and thus cell division.

10 Mar 2014

ThromboGenics receives IWT grant to study potential new biotherapeutics for DME

ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines for the back of the eye, today announces that it has been awarded a €3 million grant from the Flemish agency for Innovation by Science and Technology.

10 Mar 2014

Metallic toys, low-cost jewelry can affect children's health

We know that babies and young children often put non-food items in their mouths, a behaviour that occasionally leads to swallowing of foreign objects. Metallic toys and low-cost jewelry often contain toxic substances such as lead and cadmium.

6 Mar 2014

New study shows male hormones play important role; may enhance IVF therapy in women

Several fertility clinics across the country are beginning to administer testosterone, either through a patch or a gel on the skin, to increase the number of eggs produced by certain women undergoing in vitro fertilization (IVF).

5 Mar 2014

Plymouth University enters partnership with Brain Tumour Research

Patients, carers, scientists, clinicians and charities from across the UK are heading to Westminster today for the launch of a ground-breaking new collaborative partnership between the charity Brain Tumour Research and Plymouth University Peninsula Schools of Medicine and Dentistry. The announcement will open a new chapter in long-term sustainable and continuous research into the biggest cancer killer of children and adults under 40.

5 Mar 2014